Learning Level: Intermediate -

The SARS-CoV-2 worldwide pandemic has presented a significant challenge to business continuity for pharmaceutical manufacturing. It has led to Industry re-assessing the virus control framework, and in particular, any challenges that this may present to the mitigations currently in place. This presentation will focus on the SARS-CoV-2 situation and factors to be assessed in a GMP Biopharmaceutical manufacturing facility and whether they present a secure virus mitigation strategy to protect the product from contamination from this and other viruses.

  1. The factors involved in the virus control framework for a Biopharmaceutical manufacturing facility with reference to ICH Q5A. 
  2. The planning activities required in order to prepare for a novel virus challenge to manufacturing facilities. 
  3. Ongoing virus risk management and mitigations. 
Risk Based Approach to mitigate SARS – COV -2

Download Presentation


Anne Stokes, PhD
Director TSE and Virus Control
Thomas B. Hartman
President and CEO
Subscribe to your ISPE YouTube Channel
& Click the bell for notifications.

View All Videos